Ben Wolfson

I’m passionate about the intersections between science/technology and society, policy, and am currently thrilled to be exploring these as an American Association for the Advancement of Sciences Science and Technology Policy Fellow. I currently mostly work on innovation and basic research policy, but my interests span the field. I’m currently reading the most about science of science, innovation policy and innovation studies, the bioeconomy and biosecurity.

I’m also the Assistant Editor-in-Chief at the Journal of Science Policy and Governance, where I love being able to keep up to date with current science policy writing and research and enjoy helping early-career authors craft well written science policy analysis and articles.



Recent Posts

  • How Goliath ate David: the story of Instagram
    Sarah Frier’s deft narrative nonfiction begins as a riveting tale of startup drama, with Instagram’s historic sale to Facebook for $1 billion and a guarantee of business independence. But what follows in No Filter is the story of culture clash and an ongoing debate between curation and automation, ending with (spoiler alert!) the exit of Instagram co-founders Kevin Systrom and Mike Krieger…
  • Insect Allies and the role of DARPA in scientific research
    Last month, a Pentagon research program called Insect Allies burst into the public conversation after a team of research scientists and legal scholars published an article detailing their concerns and critiques of the project in Science magazine. Insect Allies is run by the Defense Advanced Research Projects Agency (DARPA), and was announced in 2016 with the stated goal of “pursuing scalable, readily deployable, […]
  • DARPA and the future of synthetic biology
    Synthetic biology is one of the fastest growing fields in terms of both information and capital generation. In 2012, The World Economic Forum ranked it as the second most important emerging technology of the 21st century; and while it does not explicitly appear on the 2016 list, half of the emerging technologies are enabled by […]
  • Funding is Essential for FDA Oncology Center of Excellence
    In early 2017, the Oncology Center of Excellence (OCE) was established by the U.S. Food and Drug Administration (FDA) to modernize the cancer drug approval process by increasing intra-agency collaboration and promoting novel regulatory ideas and processes. Among critical, medical innovation initiatives, the 21st Century Cures Act (Cures) directed the agency to create inter-center institutes in major disease areas […]
  • Fund Science to Fight Cancer
    This December the United States will enter the 46th year of its longest ongoing war: the war on cancer. During this time, we have lost more lives to this disease than all U.S. military casualties since the birth of our country.